Skip to main content
    S

    Sol Gel Technologies Ltd (SLGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $54.96
    -0.16 (-0.29%)

    Market Cap: $180.46M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sol Gel Technologies Ltd (SLGL) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Sol Gel Technologies are Greenwich Lifesciences (GLSI), Zentalis Pharmaceuticals Llc (ZNTL) and Palisade Bio (PALI). By market cap, Sol Gel Technologies ranks 7th of the 13 companies on this page; Galectin Therapeutics (GALT) is the largest at $307.59M.

    Peer Comparison

    SLGL's revenue growth of -96.6% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Sol Gel Technologies (SLGL)$180.46MN/A125.4x0.0%N/A-96.6%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Zentalis Pharmaceuticals Llc (ZNTL)$167.05MN/AN/A0.0%N/A0.0%0.00%
    Palisade Bio Inc (PALI)$201.01MN/A436.8x0.0%N/A0.0%0.00%
    PolyPid (PYPD)$132.25MN/AN/A0.0%N/A0.0%0.00%
    Cartesian Therapeutics Inc. (RNAC)$193.69MN/A179.8x0.0%147.2%-92.9%0.00%
    Galectin Therapeutics Inc (GALT)$307.59MN/AN/A0.0%671.1%0.0%0.00%
    Mediwound Ltd (MDWD)$185.63MN/A17.6x-235.0%-66.9%-34.2%0.00%
    enGene Therapeutics Inc. (ENGN)$161.51MN/AN/A0.0%-42.2%0.0%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Sutro Biopharma (STRO)$163.03MN/A3.4x0.0%N/A-6.1%0.00%
    Genelux Corporation Common Stock (GNLX)$84.38MN/AN/A0.0%N/A-95.3%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Peer median$176.34M12.1x13.7x0.0%52.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Sol Gel Technologies, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Zentalis Pharmaceuticals Llc (ZNTL)
    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment...
    ZNTL competitors
    Palisade Bio Inc (PALI)
    Leading BioSciences, Inc. develops therapies to improve human health through therapeutic protection of the gastrointestinal mucosal barrier.
    PALI competitors
    PolyPid (PYPD)
    PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)...
    PYPD competitors
    Cartesian Therapeutics Inc. (RNAC)
    Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs...
    RNAC competitors
    Galectin Therapeutics Inc (GALT)
    Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic...
    GALT competitors
    Mediwound Ltd (MDWD)
    MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration.
    MDWD competitors
    enGene Therapeutics Inc. (ENGN)
    enGene Holdings Inc., through its subsidiary enGene, Inc., is a clinical-stage biotechnology company that develops genetic medicines through the delivery...
    ENGN competitors
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Sutro Biopharma (STRO)
    Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company.
    STRO competitors
    Genelux Corporation Common Stock (GNLX)
    Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering...
    GNLX competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors

    Frequently Asked Questions About SLGL

    Who are Sol Gel Technologies' main competitors?

    The companies most similar to Sol Gel Technologies include Greenwich Lifesciences (GLSI), Zentalis Pharmaceuticals Llc (ZNTL), Palisade Bio (PALI), PolyPid (PYPD) and Cartesian Therapeutics (RNAC), listed from the closest match.

    Who is Sol Gel Technologies' biggest competitor?

    Galectin Therapeutics (GALT) is the largest of the similar companies at $307.59M; Greenwich Lifesciences (GLSI) is the closest match by business profile, size, sector and industry.

    How does SLGL stock compare with its competitors?

    SLGL's P/S is 125.4x against a peer median of 13.7x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Sol Gel Technologies' competitors pays a higher dividend?

    Sol Gel Technologies pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Sol Gel Technologies bigger than its competitors?

    No. Sol Gel Technologies is 7th by market cap among the 13 companies on this page; the largest is Galectin Therapeutics (GALT) at $307.59M.